Vilanterol
in BREO
What it isLong-acting beta-2 agonist, marketed only in combination; asthma and COPD.
Why this oneOnce-daily duration, which the older LABAs do not achieve.
What limits itNever as monotherapy in asthma. Tachycardia and hypokalemia at high dose; CYP3A4-dependent.
FDA-approved for
- COPD/asthma (2013)
NO BOXED WARNINGS
Principal riskTachycardia and hypokalemia; never as monotherapy in asthma
Classes and tags
Clinical profile
Mechanism of action: Vilanterol ballicule
Open Vilanterol in the interactive console ↗
Memory aids: mascots and interaction avatars
